{"id":"8-methoxypsoralen","safety":{"commonSideEffects":[{"rate":null,"effect":"Phototoxicity (erythema, blistering)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Increased risk of skin cancer with long-term use"}]},"_chembl":null,"_fixedAt":"2026-03-30T12:10:37.605822","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"8-methoxypsoralen (8-MOP) is a naturally occurring furocoumarin that belongs to the psoralen class of photosensitizing agents. When activated by long-wave ultraviolet A (UVA) radiation, it intercalates into DNA and forms thymine-psoralen photoadducts, creating interstrand crosslinks that damage DNA and induce cell death. This mechanism is particularly effective against rapidly dividing cells, making it useful in treating cutaneous T-cell lymphomas and other skin disorders.","oneSentence":"8-methoxypsoralen is a photoactive compound that intercalates into DNA and forms covalent crosslinks upon UVA exposure, triggering apoptosis in abnormal cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:54.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cutaneous T-cell lymphoma (mycosis fungoides)"},{"name":"Psoriasis"},{"name":"Vitiligo"}]},"_fixedFields":["sideEffects","modality→Small Molecule"],"trialDetails":[{"nctId":"NCT04870437","phase":"NA","title":"Impact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation.","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2022-04-27","conditions":"Kidney Transplantation","enrollment":30},{"nctId":"NCT06646016","phase":"PHASE2","title":"EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis","status":"WITHDRAWN","sponsor":"Therakos LLC","startDate":"2025-12-15","conditions":"Immune-related Colitis","enrollment":""},{"nctId":"NCT03204721","phase":"NA","title":"Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2017-06-21","conditions":"Graft-Versus-Host Disease","enrollment":158},{"nctId":"NCT05718674","phase":"","title":"Photopheresis in GvHD After Hematopoietic Transplantation: Characteristics of the Procedure and of the Cell Product","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-05-26","conditions":"Graft Vs Host Disease, Extracorporeal Photopheresis","enrollment":27},{"nctId":"NCT02181257","phase":"PHASE3","title":"Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2015-01","conditions":"Bronchiolitis Obliterans Syndrome (BOS)","enrollment":280},{"nctId":"NCT04229004","phase":"PHASE3","title":"A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Pancreatic Cancer Action Network","startDate":"2020-01-31","conditions":"Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":502},{"nctId":"NCT04986605","phase":"PHASE2","title":"Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2025-07-01","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":15},{"nctId":"NCT00179855","phase":"PHASE2, PHASE3","title":"Extracorporeal Photopheresis for Acute Graft Versus Host Disease","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2003-07","conditions":"Graft Versus Host Disease, Cancer, Stem Cell Transplantation","enrollment":10},{"nctId":"NCT05333367","phase":"NA","title":"MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-04-15","conditions":"Cutaneous T-Cell Lymphoma, Graft Vs Host Disease, Graft Rejection","enrollment":20},{"nctId":"NCT05721079","phase":"NA","title":"Extracorporeal Photopheresis (ECP) After Lung Transplantation","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-03-01","conditions":"Lung Transplant Infection, Lung Transplant Rejection","enrollment":62},{"nctId":"NCT05882331","phase":"NA","title":"Extracorporeal Photopheresis as a Possible Therapeutic Approach to Adults With Severe and Critical COVID-19","status":"COMPLETED","sponsor":"Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases","startDate":"2021-01-01","conditions":"COVID-19","enrollment":7},{"nctId":"NCT04414735","phase":"NA","title":"Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Kidney Transplant Rejection","enrollment":30},{"nctId":"NCT00045305","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-10-24","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":17},{"nctId":"NCT03109353","phase":"PHASE1, PHASE2","title":"Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease","status":"COMPLETED","sponsor":"St. Olavs Hospital","startDate":"2017-09-20","conditions":"Cutaneous T-Cell Lymphoma, Unspecified, Chronic Graft Versus Host Disease in Skin","enrollment":7},{"nctId":"NCT04792294","phase":"","title":"Multicenter Analysis of Efficacy and Outcomes of Extracorporeal Photopheresis as Treatment of Chronic Lung Allograft Dysfunction","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2005-01-01","conditions":"Lung Transplant Rejection","enrollment":800},{"nctId":"NCT02296346","phase":"NA","title":"Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis","status":"TERMINATED","sponsor":"University of Utah","startDate":"2014-10","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":13},{"nctId":"NCT00724061","phase":"NA","title":"Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-09","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT01686594","phase":"PHASE3","title":"PUVA Maintenance Therapy in Mycosis Fungoides","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2013-02","conditions":"Patch/Plaque Stage Mycosis Fungoides","enrollment":28},{"nctId":"NCT00005092","phase":"PHASE1","title":"Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1999-05-28","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":7},{"nctId":"NCT03605940","phase":"PHASE2","title":"A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2018-10-01","conditions":"Acute-graft-versus-host Disease","enrollment":78},{"nctId":"NCT00056056","phase":"PHASE3","title":"Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2003-01","conditions":"Lymphoma","enrollment":93},{"nctId":"NCT00282503","phase":"PHASE3","title":"Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease","status":"TERMINATED","sponsor":"Mallinckrodt","startDate":"2006-01","conditions":"Acute Graft-versus-Host Disease","enrollment":19},{"nctId":"NCT00639717","phase":"PHASE2","title":"Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-03","conditions":"Graft Versus Host Disease","enrollment":48},{"nctId":"NCT01824368","phase":"PHASE1, PHASE2","title":"Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.","status":"COMPLETED","sponsor":"Red de Terapia Celular","startDate":"2013-04","conditions":"Liver Transplantation, Immunosuppression","enrollment":10},{"nctId":"NCT03083574","phase":"PHASE2","title":"Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)","status":"UNKNOWN","sponsor":"Jules Bordet Institute","startDate":"2014-09","conditions":"Refractory Chronic Graft Versus Host Disease (cGVHD)","enrollment":100},{"nctId":"NCT00402714","phase":"PHASE2","title":"A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-07","conditions":"Hematologic Malignancies","enrollment":14},{"nctId":"NCT01174940","phase":"EARLY_PHASE1","title":"Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2010-06","conditions":"Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease","enrollment":22},{"nctId":"NCT02631993","phase":"","title":"Photochemotherapy and Graft-versus-leukemia in Acute-leukemia","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2014-10","conditions":"ALL, AML, Acute GVHD","enrollment":47},{"nctId":"NCT01559584","phase":"NA","title":"Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2012-03","conditions":"Alopecia Areata","enrollment":40},{"nctId":"NCT01402414","phase":"NA","title":"Narrow-band (NB)-UVB vs. Bath-PUVA and NB-UVB Plus Salt Water Baths in Atopic Dermatitis","status":"TERMINATED","sponsor":"Ruhr University of Bochum","startDate":"2011-04","conditions":"Atopic Dermatitis","enrollment":10},{"nctId":"NCT00265603","phase":"PHASE1","title":"Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Atlantic Health System","startDate":"2004-10","conditions":"Non-Small Cell Lung Cancer","enrollment":16},{"nctId":"NCT00811005","phase":"PHASE3","title":"Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2008-10","conditions":"Pustular Palmoplantar Psoriasis","enrollment":20},{"nctId":"NCT00533195","phase":"PHASE3","title":"Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT00630903","phase":"PHASE4","title":"PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides","status":"TERMINATED","sponsor":"Madrilenian Group of Cutaneous Lymphomas","startDate":"2000-01","conditions":"Cutaneous T-Cell Lymphoma (Mycosis Fungoides)","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1886,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oxsoralen®; Gerot Pharmazeutika GmbH, Vienna, Austria"],"phase":"phase_3","status":"active","brandName":"8-methoxypsoralen","genericName":"8-methoxypsoralen","companyName":"Medical University of Graz","companyId":"medical-university-of-graz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"8-methoxypsoralen is a photoactive compound that intercalates into DNA and forms covalent crosslinks upon UVA exposure, triggering apoptosis in abnormal cells. Used for Cutaneous T-cell lymphoma (mycosis fungoides), Psoriasis, Vitiligo.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}